| Clinical data | |
|---|---|
| Trade names | Revistel, Rivistel, or Rivestel |
| Other names | Iristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093 |
| Drug class | Dopamine D2 receptor antagonist; Antihypertensive agent; Antimigraine agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.072.585 |
| Chemical and physical data | |
| Formula | C17H26N4O4S |
| Molar mass | 382.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alpiropride (INN; brand name Revistel, Rivistel, or Rivestel) is a dopamine D2 receptor antagonist of the benzamide group related to sulpiride. It is described as an antihypertensive agent and has been marketed for use as an antimigraine medication in Portugal. The drug was first described by 1980 and was introduced for medical use by 1989. It remained marketed in Portugal as late as 2000.